Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||MYCi975 + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MYCi975||NUCC-0200975||c-MYC Inhibitor 9||MYCi975 is an inhibitor of MYC that blocks the interaction between Myc and Max, which leads to reduced Myc stability, thereby potentially enhancing the antitumor immune response, and inhibiting colony formation and tumor growth (PMID: 31679823).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||PD-L1/PD-1 antibody 67|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||MYCi975 + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, MYCi975 combined with an anti-PD1 therapy synergistically inhibited tumor growth in a mouse model of prostate cancer (PMID: 31679823).||31679823|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|